Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

Journal of Clinical Biochemistry and Nutrition - Japan
doi 10.3164/jcbn.15-127
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Society for Free Radical Research Japan

Related search

The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

English

Proteomic Profiling Reveals That Collismycin a Is an Iron Chelator

Scientific Reports
Multidisciplinary
2016English

Abnormal Iron Accumulation in Brain and New Iron Chelator for Labile Iron Removal Therapy

International Journal of Chemistry
2015English

Oral Corticosteroid Exposure and Adverse Effects in Asthmatic Patients

Pediatrics
Child HealthPediatricsPerinatology
2018English

An NF-kappaB- And IKK-Independent Function of NEMO Prevents Hepatocarcinogenesis by Suppressing Compensatory Liver Regeneration

Cancers
Cancer ResearchOncology
2019English

Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2010English

Combined Therapy of Iron Chelator and Antioxidant Completely Restores Brain Dysfunction Induced by Iron Toxicity

PLoS ONE
Multidisciplinary
2014English

Differential Regulation of Iron Chelator-Induced IL-8 Synthesis via MAP Kinase and NF-κB in Immortalized and Malignant Oral Keratinocytes

BMC Cancer
Cancer ResearchOncologyGenetics
2007English

Management of Oral Adverse Effects Related to Cetuximab Plus Radiotherapy

JORDI - Journal of Oral Diagnosis
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy